In summary, this study demonstrated that mutated EGFR amplification led to resistance to a third‐generation EGFR‐TKI, TAS‐121, in a patient with EGFR T790M‐positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.